Oxethazaine

Research use only, not for human use.

Oxethazaine is a topical anesthetic, in preventing acid-induced esophageal pain.

Oxethazaine is a topical anesthetic, in preventing acid-induced esophageal pain.(In Vivo):Oxetacaine (intraperitoneal injection; 5, 10, and 15 mg/kg; during days 4–11) doses induces significant conditioned place preference (CPP), and there are no differences among the groups. While its postive control group phentermine only 3 mg/kg causes significant CPP. .

——

Oxetacaine (intraperitoneal?injection; 5, 10, and 15 mg/kg; during days 4–11) doses induces significant conditioned place preference (CPP), and there are no differences among the groups. While its postive control group phentermine only 3 mg/kg causes significant CPP.. Animal Model:Male Wistar rats Dosage:5, 10, and 15 mg/kg; during days 4–11Administration:Intraperitoneal?injection Result:Showed a significant CPP in vivo.

Oxethazaine | WY 806 | Wy-806 | Oxetacaine | Emoren | FH 099

Membrane Transporter/Ion Channel

Sodium Channel

Sodium Channel

Neurological Disease

——

126-27-2

467.64

C28H41N3O3

>98% (HPLC)

Soluble in DMSO

OCCN(CC(N(C(C)(C)CC1=CC=CC=C1)C)=O)CC(N(C(C)(C)CC2=CC=CC=C2)C)=O

Acetamide, 2,2'-((2-hydroxyethyl)imino)bis(N-(1,1-dimethyl-2-phenylethyl)-N-methyl-

(-20℃)

With Ice Pack

≥ 2 years